Pierre Fabre Taps XtalPi’s AI and Robotics for Drug Discovery
What happened
On November 9, 2026, Laboratoires Pierre Fabre and XtalPi entered into a partnership to discover new small-molecule drug candidates for diseases such as cancer, rare disorders, and possibly dermatological conditions. XtalPi will use its AI and robotics platform to design new molecules, focusing on targets that have been difficult to address with existing drugs. Pierre Fabre will select the most promising compounds and handle their clinical and commercial development. The agreement includes financial terms such as upfront and milestone payments.
Key details
- The partnership was announced on November 9, 2026.
- XtalPi is responsible for de novo molecular design using AI and robotics.
- Pierre Fabre will select and advance compounds in oncology, rare diseases, and potentially dermatology.
- The deal includes upfront and milestone payments, plus downstream economic participation.
- The collaboration covers multiple research programs targeting hard-to-drug diseases.
Why it matters
Pharmaceutical researchers at Pierre Fabre gain access to XtalPi’s AI and robotics technology, which may speed up the identification of new drug candidates for diseases that have lacked effective treatments. For XtalPi, the agreement provides opportunities to apply its platform across several therapeutic areas with a clear path to clinical development. Both companies now have a defined process for moving AI-designed molecules from discovery through to potential clinical use, with financial incentives tied to progress.